Abstract : Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway disease that can be prevented and treated. The recommendations for therapy include bronchodilators from two classes (LAMA (Long Acting Muscarinic Antagonists) and LABA (Long Acting Beta2 Agonists)). Spiolto Respimat® is a LAMA/LABA combination therapy and comprises tiotropium (Spiriva®) and olodaterol (a LABA). Clinical studies show that Spiolto Respimat® is able to improve lung function tests (Increased FEV1, decreased hyperinflation and residual volume) and quality of life as compared to tiotropium or olodaterol. Studies also suggest that COPD exacerbations are decreased in patients treated by Spiolto Respimat® as compared to those treated with olodaterol (results of studies with exacerbations as primary outcome are not available yet). Safety of Spiolto Respimat® appears similar to tiotropium or olodaterol. Spiolto Respimat® indications is maintenance therapy for COPD. Reimbursement in Belgium requires that patients still display symptoms although already treated and that he/she has been previously treated by a LAMA.